GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Cyclically Adjusted Price-to-FCF

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of May. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CNBX Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CNBX Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CNBX Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, CNBX Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



CNBX Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CNBX Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, CNBX Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.004/130.9299*130.9299
=-0.004

Current CPI (Feb. 2024) = 130.9299.

CNBX Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201405 -0.127 100.373 -0.166
201408 -0.060 100.352 -0.078
201411 -0.136 99.635 -0.179
201502 -0.066 99.032 -0.087
201505 0.017 100.333 0.022
201508 -0.033 100.548 -0.043
201511 -0.043 100.135 -0.056
201602 -0.031 100.040 -0.041
201605 0.013 101.355 0.017
201608 -0.080 101.617 -0.103
201611 -0.163 101.829 -0.210
201702 -0.176 102.779 -0.224
201705 -0.212 103.256 -0.269
201708 -0.401 103.587 -0.507
201711 -0.459 104.072 -0.577
201802 -1.072 105.052 -1.336
201805 -0.562 106.148 -0.693
201808 -0.821 106.383 -1.010
201811 -0.724 106.338 -0.891
201902 -0.776 106.649 -0.953
201905 -0.788 108.048 -0.955
201908 -0.809 108.245 -0.979
201911 -0.693 108.519 -0.836
202002 -0.649 109.139 -0.779
202005 -0.566 108.175 -0.685
202008 -0.638 109.662 -0.762
202011 -0.543 109.793 -0.648
202102 -0.623 110.968 -0.735
202105 -0.544 113.576 -0.627
202108 -0.482 115.421 -0.547
202111 -0.729 117.269 -0.814
202202 -0.292 119.703 -0.319
202205 -0.303 123.323 -0.322
202208 -0.122 124.958 -0.128
202211 -0.076 125.607 -0.079
202302 -0.010 126.928 -0.010
202305 -0.002 128.314 -0.002
202308 0.001 129.538 0.001
202311 -0.003 129.548 -0.003
202402 -0.004 130.930 -0.004

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CNBX Pharmaceuticals  (OTCPK:CNBX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CNBX Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary